Navigation Links
CoDa Therapeutics Closes $19 Million Series B Financing Round
Date:4/18/2011

SAN DIEGO, April 18, 2011 /PRNewswire/ -- CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

"The financing will allow us to take essential steps for the development of CoDa; in particular, we will now conduct a large Phase 2 multicenter venous leg ulcer trial in the United States, New Zealand and Australia with Nexagon®, our lead product for chronic wound patients. In addition, we will continue the preclinical development of our product portfolio in our research laboratories," said Bradford Duft, CEO of CoDa.

CoDa is a clinical-stage biopharmaceutical company working to develop a new drug therapy for wounds that do not heal properly, including venous leg and diabetic foot ulcers.  CoDa's lead drug candidate, Nexagon® – a first-in-class compound being tested for its ability to speed healing and reduce inflammation – would be applied topically to stop over-production of a protein known as "connexin43."  CoDa discovered that chronic, poorly healing wounds are characterized by too much continuing connexin43 expression, and that suppression by Nexagon® can improve wound healing.  The company is now working under an FDA-approved IND to generate clinical data in support of eventual regulatory approval for marketing.

CoDa completed a first Phase 2 trial with Nexagon® in 98 patients with venous leg ulcers.  In the drug arm almost one third of patients were completely healed after four weeks following just three application of Nexagon® compared to only 6% complete healing in the placebo arm (p<0.02).

According to Dr. Thomas Serena, a Nexagon® study investigator and Founder and Medical Dire
'/>"/>

SOURCE CoDa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... CLARA, Calif., Feb. 18 Align Technology, Inc. (Nasdaq: ... notified of a purported declaratory judgment action filed against the ... United States District Court for the Southern District of Texas. ... 2009, but has not been served with a copy of ...
... supported entry into Company,s current Phase, ... 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that The Journal of Urology has published ... results for the Company,s proprietary Mycobacterial Cell Wall ...
... a world-leading provider of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box ... ... February 18, 2009 -- SherWeb , a global leader in ... Reseller Program last week. The newly implemented program provides IT ...
... Change" Campaign Part of International Effort to Combat Rare Diseases That Collectively ... ... CA (PRWEB) February 18, 2009 -- Students at Albany High School in ... some change to help support the first annual World Rare Disease Day, ...
... Red Wine & More , ... Mount Kisco, NY (PRWEB) February 18, ... resveratrol . It,s been shown to increase the life spans of yeast, ... School and the National Institute on Aging created a stir when they ...
... Regardless of where they are born in ... for many life-threatening disorders, a remarkable public health advance of ... today by the March of Dimes.All 50 states and the ... for 21 or more of the 29 serious genetic ...
Cached Medicine News:Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 2Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 2Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 4
... FT is an affordable full-field, autoperimeter that includes ... least 40%. It has a small footprint and ... and easy two-button operation making it not only ... FT is the workhorse of the Paradigm family ...
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
... Gentamycin sulfate is effective against gram positive ... mycoplasma, by interfering with bacterial protein synthesis ... ribosomes. Its suggested working concentration of 50 ... mammalian cells, thereby making a gentler alternative ...
... approach to practice management, built to address the ... market. OPIE was created by practicing O&P professionals ... this field, so it thinks the way you ... anything else available. If you believe there is ...
Medicine Products: